FMA
MRTX

FNY Managed Accounts’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

FNY Managed Accounts’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-1,500
Closed -$51.6K – 400
2015
Q3 		$51.6K Buy
+1,500
New +$45.3K 0.14% 129

Other funds holding MRTX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

FNY Managed Accounts's MRTX Position: Q4 2015 in Review

FNY Managed Accounts sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2015, closing a stake of 1,500 shares — an estimated $51.6K sold.

FNY Managed Accounts first reported a position in MRTX in Q3 2015 and held it in 1 quarter. The position peaked at $51.6K in Q3 2015. 80 funds tracked by Wall St. Rank hold MRTX as of Q4 2015.

  • FNY Managed Accounts reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • FNY Managed Accounts sold 1,500 Mirati Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $51.6K.
  • FNY Managed Accounts first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2015 and held it in 1 quarter.
  • FNY Managed Accounts's Mirati Therapeutics, Inc. Common Stock position peaked at $51.6K in Q3 2015.
  • 80 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2015.

Based on FNY Managed Accounts's 13F filing for Q4 2015, filed 25 Jan 2016.